

Conference Cochairs:

Andrew J. Aguirre, Dana-Farber Cancer Institute, Boston, Massachusetts
Florescia McAllister, The University of Texas MD Anderson Cancer Center, Houston, Texas
Kenneth P. Olive, Herbert Irving Comprehensive Cancer Center, New York, New York
Eileen O'Reilly, Memorial Sloan Kettering Cancer Center, New York, New York
Diane M. Simeone, University of California, San Diego, California
Colin D. Weekes, Massachusetts General Hospital, Boston, Massachusetts

FRIDAY, SEPTEMBER 25

Registration

3:00-9:00 p.m. | Indigo West Foyer

Welcome and Opening Keynote Session


6:00-8:00 p.m. | Indigo ABEF

Session Chair: Diane M. Simeone, University of California, San Diego, California

6:00-6:10	Welcome Diane M. Simeone
6:10-6:20	Comments from Lead Supporter Andrew Rakeman, The Lustgarten Foundation, Uniondale, New York
6:20-6:25	Introduction of Opening Keynote Speaker Diane M. Simeone
6:25-6:55	Targeting RAS in pancreatic cancer Andrew J. Aguirre, Dana-Farber Cancer Institute, Boston, Massachusetts
6:55-7:00	Introduction of Rising Star Speaker Diane M. Simeone
7:00-7:30	Wired for innervation: Modeling the neural niche in PDAC Eileen Carpenter, University of Michigan Medical School, Ann Arbor, Michigan
7:30-8:00	Discussion/Q&A

Opening Reception

8:00-9:30 p.m. | Promenade Plaza



SATURDAY, SEPTEMBER 26

Continental Breakfast

7:00-8:30 a.m. | Indigo CDCH

Plenary Session 1: From Detection to Interception: Redefining the Earliest Stages of Pancreatic Cancer

8:30-10:15 a.m. | Indigo ABEF

Session Chair: Diane M. Simeone, University of California, San Diego, California

- | | |
|------------|---|
| 8:30-8:35 | Introduction |
| 8:35-8:55 | Turning the tide: Transforming the paradigm from advanced treatment to early detection
Diane M. Simeone |
| 8:55-9:15 | Getting ahead of the tumor: Interception approaches for pancreatic cancer
Ben Z. Stanger, University of Pennsylvania, Philadelphia, Pennsylvania |
| 9:15-9:35 | Who should we target? Defining high-risk populations for pancreatic cancer early detection and interception
Nuria Malats, Spanish National Cancer Research Centre, Madrid, Spain |
| 9:35-9:42 | Surveillance-detected pancreatic cancers: Updated report from the PRECEDE Consortium*
Raymond Wadlow, Inova Health System, Fairfax, Virginia |
| 9:42-9:49 | Reinforcing acinar identity through NR5A2 enables pancreatic cancer interception by preventing and reversing precancer*
Sahar Nissim, Dana-Farber Cancer Institute, Boston, Massachusetts |
| 9:49-10:15 | Discussion / Q&A |

Break


10:15-10:30 a.m. | Indigo West Foyer

Stephenson Global Prize Award Presentation and Honorary Lecture

10:45 a.m.-12:00 p.m. | Indigo ABEF

Lunch on Own / Free Time

12:00-2:00 p.m.



Plenary Session 2: Pancreatic Cancer Biology: From Mechanism to Disease Evolution

2:00-3:45 p.m. | Indigo ABEF

Session Chair: Andrew J. Aguirre, Dana-Farber Cancer Institute, Boston, Massachusetts

- | | |
|-----------|---|
| 2:00-2:05 | Introduction |
| 2:05-2:25 | Organelle-driven metabolic adaptation in pancreatic cancer progression
Rushika M. Perera, University of California, San Francisco, California |
| 2:25-2:45 | Molecular and clinical divergence of KRAS mutants in pancreatic cancer
Rohit Chandwani, Weill Cornell Medicine, New York, New York |
| 2:45-3:05 | Plasma WGS in pancreatic cancer
Faiyaz Notta, University of Toronto, Toronto, Ontario, Canada |
| 3:05-3:12 | Mutant GNAS-mediated epithelial IL-33 upregulation promotes IPMN initiation and progression*
Yuki Makino, The University of Osaka Department of Gastroenterology and Hepatology, Suita, Japan |
| 3:12-3:19 | Inflammation links KRAS-driven tumor biology to adverse host phenotypes in pancreatic cancer*
Dina L. Tataran, University of Glasgow, Glasgow, United Kingdom |
| 3:19-3:45 | Discussion / Q&A |

Break


3:45-4:00 p.m. | Indigo West Foyer

Plenary Session 3: Integrating AI and Multi-Omics in Precision Cancer Modeling

4:00-5:45 p.m. | Indigo ABEF

Session Chair: Colin D. Weekes, Massachusetts General Hospital, Boston, Massachusetts

- | | |
|-----------|--|
| 4:00-4:05 | Introduction |
| 4:05-4:25 | From multi-omics to autonomous artificial intelligence agents in pancreatic cancer
Enrique Velázquez Villareal, City of Hope Comprehensive Cancer Center, Duarte, California |
| 4:25-4:45 | Computationally assisted patient finding of pancreatic cancer for improving care delivery and research
Daniel Alexander King, Monter Cancer Center, Lake Success, New York |



- 4:45-5:05 **Toward a predictive science of pancreatic cancer: AI-guided multimodal and spatial oncology for detection, prognosis, and target discovery**
Joo Kyung Park, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
- 5:05-5:12 **The basal cell state maintains pancreatic cancers by controlling an immunosuppressive cell circuit***
Kate Ryan, Memorial Sloan Kettering Cancer Center, New York, New York
- 5:12-5:19 **A time-to-event model for pancreatic cancer risk prediction across multiple future intervals using longitudinal structured electronic health records***
Jifan Gao, Dana-Farber Cancer Institute, Boston, Massachusetts
- 5:19-5:45 Discussion / Q&A

Break

5:45-6:00 p.m.

Poster Session A / Reception

6:00-8:00 p.m. | Indigo CDCH

SUNDAY, SEPTEMBER 27


Continental Breakfast

7:00-8:30 a.m. | Indigo CDCH

“Meet the Expert” Roundtables Session:

7:15-8:15 a.m. | Indigo CDCH

Balancing clinical and research responsibilities Ben Stanger Rohit Chandwani	Choosing a career path: Academia vs. industry Elana Fertig
Encouraging diversity in your team Enrique Velazquez Villarreal	Conducting translational research: How to get started Rosalie Sears Kenneth Olive




Collaborating with industry Thomas George	EU/UK Collaborations Benedikt Westphalen
Getting tenure Min Li Linghua Wang	Starting your lab Yuliya Pylayeva-Gupta
How to get a paper published Andreas Trumpp	Careers in government-FDA Lola Fashoyin-Aje
How to write a grant Rushika Perera	Entrepreneurship Hartland Jackson
Editor-in-house Michele Hartsough, Senior Editor, Cancer Discovery	

Plenary Session 4: The Desmoplastic and Neural Microenvironment of Pancreatic Cancer

8:30-10:15 a.m. | Indigo ABEF

Session Chair: Andreas Trumpp, German Cancer Research Center, Heidelberg, Germany

- | | |
|-----------|--|
| 8:30-8:35 | Introduction |
| 8:35-8:55 | Profiling and targeting innervating peripheral neurons in pancreatic cancer
Andreas Trumpp, German Cancer Research Center, Heidelberg, Germany |
| 8:55-9:15 | Extracting mechanisms of cell crosstalk in pancreatic cancer using spatial and single-cell multi-omics
Nina Steele, University of Cincinnati, Cincinnati, Ohio |
| 9:15-9:35 | Battling a powerful enemy: Understanding pancreatic cancer cachexia
Min Li, University of Oklahoma Health Campus, Oklahoma City, Oklahoma |
| 9:35-9:42 | Integrated spatial proteomics of human PDAC uncovers an expanded tumor-immune-stroma spectrum with genomic associations*
Noor Shakfa, Lunenfeld-Tanenbaum Research Institute, Toronto, Ontario, Canada |



- 9:42-9:49 **EMT-associated focal adhesion signaling mediates resistance to RAS inhibition**
Joshua H. Choe, Dana-Farber Cancer Institute, Boston, Massachusetts
- 9:49-10:15 Discussion / Q&A

Break

10:15-10:30 a.m. | Indigo West Foyer

Plenary Session 5: Reimagining Immunotherapy in Pancreatic Cancer


10:30 a.m.-12:15 p.m. | Indigo ABEF

Session Chair: Florencia McAllister, The University of Texas MD Anderson Cancer Center, Houston, Texas

- 10:30-10:35 Introduction
- 10:35-10:55 **Targeting tumors as ecosystems**
Florencia McAllister
- 10:55-11:15 **Targeting the antigen landscape that emerges after KRAS inhibition for PDAC immunotherapy**
Alex Jaeger, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
- 11:15-11:35 **Determinants of B cell fate and function in cancer**
Yuliya Pylayeva-Gupta, University of North Carolina, Chapel Hill, North Carolina
- 11:35-11:42 **A mutant KRAS-targeted peptide vaccine in combination with RAS(ON) multi-selective inhibition and immune checkpoint modulators enhances anti-tumor immunity in preclinical PDAC models***
Zirui Zhu, Johns Hopkins University, Baltimore, Maryland
- 11:42-11:49 **CD4+ T cells instruct cancer-associated fibroblasts to promote immune control of pancreatic cancer**
Jessica Hung, University of California, Berkeley, California
- 11:49-12:15 Discussion / Q&A

Lunch on Own / Free Time

12:15-2:00 p.m.



Plenary Session 6: The 3 Rs of RAS Inhibition: Response, Resistance, and Rational Combinations

2:00-3:45 p.m. | Indigo ABEF

Session Chair: Kenneth P. Olive, Herbert Irving Comprehensive Cancer Center, New York, New York

- | | |
|-----------|---|
| 2:00-2:05 | Introduction |
| 2:05-2:25 | Cytotoxic chemotherapy potentiates RAS inhibition by constraining adaptive plasticity
Kenneth P. Olive |
| 2:25-2:45 | Two paths forward with RAS: Rational combination strategies and translational discovery
Arsen Osipov, Cedars-Sinai Medical Center, Los Angeles, California |
| 2:45-3:05 | Genetic co-gain in MYC and KRAS drives resistance to targeting KRAS signaling in pancreatic ductal adenocarcinoma
Rosalie Sears, Oregon Health and Science University, Portland, Oregon |
| 3:05-3:12 | Digenic CRISPR screening identifies novel KRAS/FGFR combination therapies for pancreatic cancer*
Richard Y. Ebright, Broad Institute, Boston, Massachusetts |
| 3:12-3:19 | Encoding adaptive mechanisms of resistance to KRAS inhibition in pancreatic cancer*
Qingxiang Lin, Massachusetts General Cancer Center, Boston, Massachusetts |
| 3:19-3:45 | Discussion / Q&A |

Break

3:45-4:00 p.m. | Indigo West Foyer

Panel Discussion: "Accelerating First-in-Human Oncology Trials Through Regulatory Innovation"

4:00-5:00 p.m. | Indigo ABEF

Moderator: Diane M. Simeone, University of California, San Diego, California

Panelists:

- Lola Fashoyin-Aje, AstraZeneca, Gaithersburg, Maryland
- Thomas George, University of Florida Health Cancer Center, Gainesville, Florida
- Daniel Alexander King, Monter Cancer Center, Lake Success, New York

Topics:

- Are Current Clinical Trial Models Keeping Pace with Innovation in Pancreatic Cancer?
- How Can the U.S. Remain at the Forefront of First-in-Human Oncology Drug Development?

- What Regulatory Innovations Can Accelerate First-in-Human and Novel Combination Trials?

Poster Session B / Reception

5:00-7:00 p.m. | Indigo CDCH

MONDAY, SEPTEMBER 28

Continental Breakfast

7:00-8:30 a.m. | Indigo CDCH

Plenary Session 7: Smarter Clinical Trials and Precision Development


8:30-10:15 a.m. | Indigo ABEF

Session Chair: Eileen O'Reilly, Memorial Sloan Kettering Cancer Center, New York, New York

8:30-8:35	Introduction
8:35-8:55	Changing the paradigm: Novel trial designs in pancreatic cancer Eileen O'Reilly
8:55-9:15	A multifaceted analysis of PDAC plasticity in patients Colin D. Weekes, Massachusetts General Hospital, Boston, Massachusetts
9:15-9:35	A new perspective: Clinical trials in the era of RAS inhibitors Christoph Benedikt Westphalen, Ludwig Maximilian University of Munich, Munich, Germany
9:35-9:42	Navlimetostat (BMS-986504) with or without gemcitabine (GEM) + nab-paclitaxel (nab-P) in patients (pts) with pancreatic ductal adenocarcinoma (PDAC) and homozygous MTAP deletion (MTAP-del) from CA240-0007* Tanios Bekaii-Saab, Mayo Clinic, Phoenix, Arizona
9:42-9:49	Integrated translational analyses of the first-generation KRAS G12D degrader setidegrasib identify mechanisms of response and resistance and offer rational combination strategies in pancreatic cancer* Wungki Park, Memorial Sloan Kettering Cancer Center, New York, New York
9:49-10:15	Discussion / Q&A

Break

10:15-10:30 a.m. | Indigo West Foyer



Plenary Session 8: Spatial Biology and Actionable Tumor Ecosystems: Beyond the Pretty Picture

10:30 a.m.-12:15 p.m. | Indigo ABEF

Session Chair: Elana Fertig, University of Maryland, Baltimore, Maryland

- | | |
|-------------|---|
| 10:30-10:35 | Introduction |
| 10:35-10:55 | Forecasting the interplay between tumor-CAF-immune ecosystems by integrating spatial multiomics and mechanistic mathematical modeling
Elana Fertig |
| 10:55-11:15 | Spatial microenvironment alterations across the clinical spectrum and genomic landscape of human PDAC
Hartland Jackson, Lunenfeld-Tanenbaum Research Institute, Toronto, ON, Canada |
| 11:15-11:35 | Decoding actionable tumor ecosystems through spatial multi-omics and AI
Linghua Wang, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 11:35-11:42 | High-plex spatial phenotyping resolves immune organization in pancreatic ductal adenocarcinoma*
Deniz G. Olgun, Massachusetts General Hospital, Boston, Massachusetts |
| 11:42-11:49 | Clonal heterogeneity in human pancreatic ductal adenocarcinoma and its impact on tumor progression*
Sungsik Kim, UC San Diego, La Jolla, California |
| 11:49-12:15 | Discussion / Q&A |

Closing Remarks and Departure

12:15-12:30 p.m.

Florencia McAllister, The University of Texas MD Anderson Cancer Center, Houston, Texas

Eileen O'Reilly, Memorial Sloan Kettering Cancer Center, New York, New York